1. Show article details.

    BRIEF-Optinose Announces Xhance Co-Promotion Agreement With Kaléo

    Reuters – 5:42 PM ET 07/08/2020

    OptiNose Inc (OPTN): * OPTINOSE ANNOUNCES XHANCE CO-PROMOTION AGREEMENT WITH KALÉO Source text for Eikon: Further company coverage:

  2. Show article details.

    Optinose Announces XHANCE Co-Promotion Agreement with Kaléo

    GlobeNewswire – 4:15 PM ET 07/08/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions, to co-promote XHANCE® exhalation nasal spray 93 mcg, for the treatment of nasal polyps in patients 18 year...

  3. Show article details.

    BRIEF-Optinose Announces Anti-COVID-19 Product Candidate

    Reuters – 8:11 AM ET 06/30/2020

    OptiNose Inc (OPTN): * OPTINOSE ANNOUNCES ANTI-COVID-19 PRODUCT CANDIDATE Source text for Eikon: Further company coverage:

  4. Show article details.

    Optinose Announces Anti-COVID-19 Product Candidate

    GlobeNewswire – 8:00 AM ET 06/30/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced initiation of development of a new product candidate, OPN-019.

  5. Show article details.

    Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

    GlobeNewswire – 8:30 AM ET 06/22/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET.

  6. Show article details.

    Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

    GlobeNewswire – 10:00 AM ET 06/19/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category for the third year in a row. “We are extremely proud of the culture we have built at Optinose (OPTN) over the last ten years.

  7. Show article details.

    Optinose to Host its Annual Meeting of Stockholders in Virtual Format

    GlobeNewswire – 4:30 PM ET 05/27/2020

    OptiNose, Inc. (OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders will now be held by means of a virtual format only. Online access to the meeting will begin at 8:15 am Eastern Time.

  8. Show article details.

    Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference

    GlobeNewswire – 9:00 AM ET 05/26/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 p.m. ET.

  9. Show article details.

    Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    GlobeNewswire – 4:15 PM ET 05/14/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 10:20 a.m. ET.

  10. Show article details.

    BRIEF-Optinose Reports Quarterly Loss Per Share Of $0.63

    Reuters – 4:56 PM ET 05/07/2020

    OptiNose Inc (OPTN): * OPTINOSE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL UPDATES. * Q1 REVENUE $7.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $7.8 MILLION. * SAYS DUE TO ADVERSE EFFECT OF COVID-19 PANDEMIC, CO WITHDRAWING ITS PREVIOUS XHANCE REVENUE GUIDANCE FOR 2020.

  11. Show article details.

    Optinose Reports First Quarter 2020 Financial Results and Operational Updates

    GlobeNewswire – 4:01 PM ET 05/07/2020

    Company reports first quarter 2020 XHANCE net revenue of $7.1 million First quarter 2020 XHANCE prescriptions increased 149% from first quarter 2019 Conference call and webcast to be held today at 4:15 p.m. Eastern Time YARDLEY, Pa., May 07, 2020 -- Optinose , a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today reported financial results ...

  12. Show article details.

    Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020

    GlobeNewswire – 4:15 PM ET 04/30/2020

    Conference Call and Webcast Scheduled for Thursday, May 7 at 4:15 p.m. Eastern Time Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the Company will report financial results for the first quarter 2020 and corporate updates, after market close on Thursday, May 7, 2020.

  13. Show article details.

    BRIEF-Optinose Repaying $4.4 Mln Loan Received Under Small Business Administration Paycheck Protection Program

    Reuters – 7:55 AM ET 04/24/2020

    OptiNose Inc (OPTN): * OPTINOSE (OPTN) - REPAYING $4.4 MILLION LOAN RECEIVED UNDER SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM Source text: https://bit.ly/2yCakcy Further company coverage:

  14. Show article details.

    BRIEF-Optinose Unit Applies For $4.4 Mln Loan Under SBA Paycheck Protection Program

    Reuters – 4:13 PM ET 04/16/2020

    OptiNose Inc (OPTN): * OptiNose Inc (OPTN) - UNIT APPLIED UNDER THE SBA PAYCHECK PROTECTION PROGRAM OF THE CARES ACT FOR A LOAN OF $4.4 MILLION Source text: Further company coverage:

  15. Show article details.

    Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights

    GlobeNewswire – 6:30 AM ET 03/05/2020

    Company reports fourth quarter and full year 2019 XHANCE net revenue of $11.1 million and $30.4 million Fourth quarter 2019 XHANCE prescriptions increased 26% from third quarter 2019 Company expects full-year 2020 XHANCE net revenue to more than double Company expects top-line results from both clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in the second half o...

  16. Show article details.

    Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020

    GlobeNewswire – 4:30 PM ET 02/27/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the Company will release financial results for the fourth quarter and year-end 2019, before market open on Thursday, March 5, 2020.

  17. Show article details.

    Optinose Appoints Victor Clavelli as Chief Commercial Officer

    GlobeNewswire – 7:00 AM ET 02/19/2020

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the appointment of Victor M. Clavelli as Chief Commercial Officer. Mr. Clavelli joins Optinose (OPTN) from Pfizer where, in the course of an accomplished 20-year career, he held leadership roles including marketing, sales, and regulatory affairs.

Page:

Today's and Upcoming Events

  • Aug
    14

    OPTN to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    OPTN announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.